Achieve has late-stage cytisinicline data, an accepted smoking-cessation NDA, and a fresh financing. The catch is that management now expects a manufacturing-driven FDA Complete Response Letter before any U.S. launch.
References
Sources used in this report
SEC submissionsSEC submissions JSON for CIK 00009498582026-05-13 · Issuer identity, ticker, exchange, headquarters, SIC, fiscal year end, filer status, and filing inventory.SEC XBRL companyfactsSEC companyfacts for CIK 00009498582026-05-13 · Standardized financial fact cross-check for cash, securities, debt, expenses, losses, share count, and accumulated deficit.Annual reportFY2025 Form 10-K2026-03-24 · Business description, cytisinicline mechanism, clinical data, NDA status, vaping program, Sopharma license, manufacturing, FY2025 financials, and risks.Quarterly reportQ1 2026 Form 10-Q2026-05-12 · Q1 financials, cash, debt, accumulated deficit, April financing impact, expected CRL, Adare manufacturing pivot, launch timing, and risk updates.Earnings releaseQ1 2026 earnings release, Exhibit 99.12026-05-12 · Management update on expected CRL, Adare, financing, leadership transition, Q1 financial results, smoking PDUFA date, and vaping milestones.Earnings releaseFY2025 earnings release, Exhibit 99.12026-03-24 · FY2025 cash, operating expenses, net loss, NDA acceptance, ORCA-OL safety work, and vaping-program update.Governance filingFY2025 Form 10-K/A2026-04-30 · Board independence, leadership structure, committees, executive compensation, incentive design, ownership, related parties, clawback, and annual-meeting matters.Current reportApril 2026 private placement Form 8-K2026-04-16 · Securities purchase agreement, financing terms, warrants, board designation rights, CEO transition, director appointments, registration rights, and use of proceeds.Press releaseApril 2026 private placement press release, Exhibit 99.12026-04-16 · Investor syndicate, upfront proceeds, possible warrant proceeds, intended uses, and management commentary.